Alnylam Pharmaceuticals (NASDAQ:ALNY) Stock Price Expected to Rise, Citigroup Analyst Says

Alnylam Pharmaceuticals (NASDAQ:ALNY - Get Free Report) had its price objective hoisted by investment analysts at Citigroup from $364.00 to $404.00 in a research report issued on Friday,Benzinga reports. The firm currently has a "buy" rating on the biopharmaceutical company's stock. Citigroup's price target would suggest a potential upside of 27.95% from the company's current price.

Other equities analysts have also issued reports about the stock. Canaccord Genuity Group boosted their price target on shares of Alnylam Pharmaceuticals from $385.00 to $390.00 and gave the company a "buy" rating in a research report on Friday, March 21st. Stifel Nicolaus boosted their price target on shares of Alnylam Pharmaceuticals from $300.00 to $345.00 and gave the company a "buy" rating in a research report on Monday, March 31st. Wells Fargo & Company boosted their price target on shares of Alnylam Pharmaceuticals from $287.00 to $333.00 and gave the company an "equal weight" rating in a research report on Monday, June 30th. Morgan Stanley reduced their price target on shares of Alnylam Pharmaceuticals from $284.00 to $268.00 and set an "equal weight" rating on the stock in a research report on Friday, April 11th. Finally, BMO Capital Markets boosted their price target on shares of Alnylam Pharmaceuticals from $300.00 to $360.00 and gave the company an "outperform" rating in a research report on Tuesday, June 24th. One research analyst has rated the stock with a sell rating, three have issued a hold rating and twenty-two have issued a buy rating to the company. According to MarketBeat.com, the stock currently has an average rating of "Moderate Buy" and a consensus price target of $345.70.

Alnylam Pharmaceuticals Price Performance

NASDAQ ALNY traded up $0.81 on Friday, reaching $315.75. The company's stock had a trading volume of 629,558 shares, compared to its average volume of 854,540. The firm has a market cap of $41.17 billion, a PE ratio of -151.08 and a beta of 0.23. The business has a 50-day moving average price of $301.17 and a 200 day moving average price of $269.13. Alnylam Pharmaceuticals has a 52 week low of $205.87 and a 52 week high of $333.70. The company has a current ratio of 3.04, a quick ratio of 2.98 and a debt-to-equity ratio of 8.88.

Alnylam Pharmaceuticals (NASDAQ:ALNY - Get Free Report) last posted its earnings results on Thursday, May 1st. The biopharmaceutical company reported ($0.44) earnings per share for the quarter, missing analysts' consensus estimates of ($0.37) by ($0.07). The business had revenue of $594.19 million during the quarter, compared to the consensus estimate of $584.32 million. Alnylam Pharmaceuticals had a negative net margin of 11.49% and a negative return on equity of 510.31%. The business's revenue was up 20.2% compared to the same quarter last year. During the same period in the previous year, the firm earned ($0.16) EPS. Sell-side analysts expect that Alnylam Pharmaceuticals will post -1.7 EPS for the current year.

Insiders Place Their Bets

In other Alnylam Pharmaceuticals news, CEO Yvonne Greenstreet sold 19,297 shares of the stock in a transaction on Monday, June 2nd. The shares were sold at an average price of $306.00, for a total value of $5,904,882.00. Following the sale, the chief executive officer directly owned 48,948 shares in the company, valued at approximately $14,978,088. This trade represents a 28.28% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is accessible through the SEC website. Company insiders own 1.20% of the company's stock.

Institutional Investors Weigh In On Alnylam Pharmaceuticals

Hedge funds have recently bought and sold shares of the company. Larson Financial Group LLC raised its holdings in Alnylam Pharmaceuticals by 187.2% in the fourth quarter. Larson Financial Group LLC now owns 112 shares of the biopharmaceutical company's stock worth $26,000 after purchasing an additional 73 shares during the period. SVB Wealth LLC bought a new stake in shares of Alnylam Pharmaceuticals during the first quarter worth $27,000. Park Square Financial Group LLC bought a new stake in shares of Alnylam Pharmaceuticals during the fourth quarter worth $28,000. Whipplewood Advisors LLC increased its position in shares of Alnylam Pharmaceuticals by 208.8% during the first quarter. Whipplewood Advisors LLC now owns 105 shares of the biopharmaceutical company's stock worth $28,000 after acquiring an additional 71 shares in the last quarter. Finally, Bessemer Group Inc. increased its position in shares of Alnylam Pharmaceuticals by 176.9% during the first quarter. Bessemer Group Inc. now owns 108 shares of the biopharmaceutical company's stock worth $29,000 after acquiring an additional 69 shares in the last quarter. 92.97% of the stock is currently owned by institutional investors and hedge funds.

Alnylam Pharmaceuticals Company Profile

Alnylam Pharmaceuticals, Inc, a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics based on ribonucleic acid interference. Its marketed products include ONPATTRO (patisiran) for the treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults; AMVUTTRA for the treatment of hATTR amyloidosis with polyneuropathy in adults; GIVLAARI for the treatment of adults with acute hepatic porphyria; and OXLUMO for the treatment of primary hyperoxaluria type 1.